NCT05134012
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
Active, Not Recruiting
PHASE3Ages 18+InterventionalDiagnosticMedTrace Pharma A/S
~215 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
At a glance
Recruiting sites
0 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity and specificity of the [15-O]-H2O PET study using the truth-standard of ICA with FFR/iFR or CCTA.
Measured over 30 days
Conditions
Where it's being run
13 sites across 11 statesGermany2
Sweden2
Iowa1
Minnesota1
Missouri1
Pennsylvania1
Texas1
Virginia1
Study leadership
- Nicholas Borys, MD · STUDY_DIRECTOR · MedTrace Pharma A/S
- Marcelo DiCarli, MD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Sensitivity and specificity of the [15-O]-H2O PET study using the truth-standard of ICA with FFR/iFR or CCTA.30 days
Sensitivity and specificity are defined as follows: * True Positives (TP): Subjects with abnormal PET MPI and disease positive by the truth standard * True Negatives (TN): Subjects with normal PET MPI and disease negative by the truth standard * False Positives (FP): Subjects with abnormal PET MPI and disease negative by the truth standard * False Negatives (FN): Subjects with normal PET MPI and disease positive by the truth standard * Sensitivity: TP/(TP + FN) * Specificity: TN/(TN + FP)